Twenty-five selected cases of clinically confirmed pancreatic adenocarcinoma (see Figure 1) were evaluated for all three markers, of which 80% of the cases stained positive for SMAD4, while 100% of the cases were positive for CK19 and CA19-9. Here, SMAD4 is linked to pancreatic adenocarcinoma.